My estimation is $INO
will be above $300 in January 2021
Phase 3 human trials of VGX-3100 against Cervical Cancer
Inovio expects to report VGX-3100 REVEAL 1 top-line efficacy data in the fourth quarter of 2020. Through extensive work on amending the clinical readout timing a year earlier than originally designed, these early top-line data will be made available without compromising the integrity of both REVEAL 1 and REVEAL 2 trials. If positive, Phase 3 top-line data could provide further regulatory validation for this first-in-class DNA Medicine for treating cervical dysplasia.
Cervical Cancer Treatment Market Size Worth USD 10.6 Billion By 2025
Video about successful treatment of Cervical Cancer by Inovio DNA vaccine 5 years ago